CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.

Beauty & Cosmetics

CUTISS

Daniela Marino

Adeline Beaupoil

Stella Nuber

Nathalie Moro

Miralda Salaji

Mei Chien Wong Brawand

Janine Meier

Chiara Pagliuca

Stefano Marchesani

Jackie Vuistiner

Vincent Ronfard

Barnes Laurent

Kathi Mujynya

Joaquin Urdinez

Fabienne Hartmann-Fritsch

Darjan Andrejc

Anna-Lena Murphy-Dittrich

Andreea Iordan

The Research and Development team at CUTISS is dedicated to innovating and refining the bio-engineering processes for producing customized human skin grafts, specifically denovoSkin™. This multidisciplinary team collaborates on research initiatives, clinical trials, and the development of protocols to ensure the safety and efficacy of their products, ultimately advancing treatments for burn victims and enhancing patient outcomes.

Research and Development

Operations Management

Quality Assurance

Research and Development

About

Team members

Other teams at CUTISS

Operations Management

Quality Assurance